These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 10831638)

  • 21. High-efficiency dialysis with PMMA dialyzers: treatment dose delivery and long-term results.
    David S; Cambi V
    Contrib Nephrol; 1999; 125():96-110. PubMed ID: 9895434
    [No Abstract]   [Full Text] [Related]  

  • 22. Using AN69 ST membrane: a dialysis centre experience.
    Maheut H; Lacour F
    Nephrol Dial Transplant; 2001 Jul; 16(7):1519-20. PubMed ID: 11427664
    [No Abstract]   [Full Text] [Related]  

  • 23. β-trace protein is highly removed during haemodialysis with high-flux and super high-flux membranes.
    Donadio C; Tognotti D; Caponi L; Paolicchi A
    BMC Nephrol; 2017 Feb; 18(1):68. PubMed ID: 28219328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Choice of modality with the use of high-performance membrane and evaluation for clinical effects.
    Masakane I
    Contrib Nephrol; 2011; 173():84-94. PubMed ID: 21865780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AN69: Evolution of the world's first high permeability membrane.
    Thomas M; Moriyama K; Ledebo I
    Contrib Nephrol; 2011; 173():119-129. PubMed ID: 21865784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biocompatibility of PMMA membranes in acute and chronic patients with renal failure.
    Manzoni C; Locatelli F
    Contrib Nephrol; 1999; 125():65-75. PubMed ID: 9895431
    [No Abstract]   [Full Text] [Related]  

  • 27. Synthetically modified cellulose: an alternative to synthetic membranes for use in haemodialysis?
    Hoenich NA; Woffindin C; Stamp S; Roberts SJ; Turnbull J
    Biomaterials; 1997 Oct; 18(19):1299-303. PubMed ID: 9307219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leukocyte adhesion molecules and leukocyte-platelet interactions during hemodialysis: effects of different synthetic membranes.
    Sirolli V; Ballone E; Amoroso L; Di Liberato L; Di Mascio R; Capelli P; Albertazzi A; Bonomini M
    Int J Artif Organs; 1999 Aug; 22(8):536-42. PubMed ID: 10533909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results from EuCliD (European Clinical Dialysis Database): impact of shifting treatment modality.
    Merello Godino JI; Rentero R; Orlandini G; Marcelli D; Ronco C
    Int J Artif Organs; 2002 Nov; 25(11):1049-60. PubMed ID: 12487392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative analysis of the efficacy and biocompatibility of various methods of dialysis].
    Zivanović M; Hrvacević R; Kovacević Z; Veljancić L; Vujanić S
    Vojnosanit Pregl; 2005 Oct; 62(10):725-9. PubMed ID: 16305099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of 131I-beta2 microglobulin in hemodialysis patients: assessment using total body counting.
    Chanard J; Caudwell V; Valeire J; Vincent C; Randoux C; Wuillai A; Wynckel A
    Artif Organs; 1998 Jul; 22(7):574-80. PubMed ID: 9684694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Amyloidosis of the dialysis patient].
    van Ypersele de Strihou C
    Bull Mem Acad R Med Belg; 1988; 143(10-12):456-65; discussion 465-7. PubMed ID: 3077074
    [No Abstract]   [Full Text] [Related]  

  • 33. Biocompatibility study on cuprophane and polysulphone dialysers.
    Taraba I; Polner K; Makó J
    Nephrol Dial Transplant; 1991; 6 Suppl 3():22-5. PubMed ID: 1775261
    [No Abstract]   [Full Text] [Related]  

  • 34. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD.
    McKane W; Chandna SM; Tattersall JE; Greenwood RN; Farrington K
    Kidney Int; 2002 Jan; 61(1):256-65. PubMed ID: 11786108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case control study on dialysis arthropathy: the influence of two different dialysis membranes: data from the EDTA Registry.
    Brunner FP; Brynger H; Ehrich JH; Fassbinder W; Geerlings W; Rizzoni G; Selwood NH; Tufveson G; Wing AJ
    Nephrol Dial Transplant; 1990; 5(6):432-6. PubMed ID: 2122319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Beneficial effect of AN69 membranes on anemia in hemodialyzed patients].
    García Cortés MJ; Sánchez Perales MC; Liébana A; Gil JM; Borrego FJ; Borrego J; Pérez del Barrio P; Serrano P; Pérez Bañasco V
    Nefrologia; 2001; 21(4):370-5. PubMed ID: 11816513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behaviour of clearances and diffusive permeability during hemodialysis with PMMA dialyzers: clinical study.
    Ghezzi PM; Canepari G; Ronco C
    Contrib Nephrol; 1999; 125():53-64. PubMed ID: 9895430
    [No Abstract]   [Full Text] [Related]  

  • 38. High-permeable membranes and hypersensitivity-like reactions: role of dialysis fluid contamination.
    Bigazzi R; Atti M; Baldari G
    Blood Purif; 1990; 8(4):190-8. PubMed ID: 2085427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients.
    Pickett TM; Cruickshank A; Greenwood RN; Taube D; Davenport A; Farrington K
    Blood Purif; 2002; 20(2):161-6. PubMed ID: 11818679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients.
    Stein G; Franke S; Mahiout A; Schneider S; Sperschneider H; Borst S; Vienken J
    Nephrol Dial Transplant; 2001 May; 16(5):999-1008. PubMed ID: 11328907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.